Biophysical Therapeutics Launches IF1 Longevity Skincare Brand
Biophysical Therapeutics has launched its new consumer longevity brand, IF1, featuring an anti-aging moisturizer. The company will reinvest profits from the skincare line into its drug development programs.
Delaware-based biotechnology company Biophysical Therapeutics has introduced IF1, a new consumer brand focused on longevity science. The company is currently accepting pre-orders for its inaugural product: an anti-aging skin moisturizer.
The IF1 moisturizer incorporates the company's research into the biological mechanisms of aging. The initial production run is limited to 500 units, with each retailing at $120. Profits generated from IF1 product sales are designated to fund Biophysical Therapeutics' drug development pipeline, which targets cancer, age-related diseases like Alzheimer's, and the aging process itself.
Founded in 2022 by Dr. Michael Forrest, Biophysical Therapeutics specializes in computational biology and biophysical modeling. The company has previously developed and patented experimentally validated drugs. The science behind IF1 is based on the company's findings that the longevity protein IF1 is linked to lifespan across mammal species, and that increasing IF1 levels can slow aging in mice.
Given the substantial and growing global market for anti-aging skincare, Biophysical Therapeutics aims to leverage the IF1 brand to generate revenue that supports its more fundamental research into extending human healthspan and lifespan.